Steroids
Also known as: Corticosteroids, Glucocorticoids
Methodology & AI Transparency ⓘ
Steroids Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: You may have heard of anabolic steroids , which can have harmful effects.
- 2 Real-world patient consensus: Mapped to Dermatology: Acne, Eczema, Psoriasis & Rosacea under ICD-10-CM L70.8 for Steroids clinical workups.
- 3 Typical cash cost range: Workup highlights for Steroids (L70.8): or targeted biologics [Steroids L70.8].
- 4 Top reported side effects / signs: Follow-up benchmark in Steroids: maintaining Fasting Lipids & in Steroids (L70.8: ALT (if systemic) within Within baseline reference limits (L70.8).
Ask our AI Specialists anything about Steroids
What Is Steroids?
You may have heard of anabolic steroids , which can have harmful effects. But there's another type of steroid - sometimes called a corticosteroid - that treats a variety of problems. These steroids are similar to hormones that your adrenal glands make to fight stress associated with illnesses and injuries. They reduce inflammation and affect the immune system. You may need to take corticosteroids to treat: Arthritis Asthma Autoimmune diseases such as lupus and multiple sclerosis Skin conditions such as eczema and rashes Some kinds of cancer Steroids are strong medicines, and they can have side effects, including weakened bones and cataracts.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Steroids (code L70.8) is or pilosebaceous follicular in Steroids (L70.8: hyperkeratinization), Cross-referenced with NIH MeSH (Glucocorticoids, Adrenal Cortex Hormones), which Dermatology: Acne, Eczema, Psoriasis & Rosacea clinicians address while surveilling Fasting Lipids & in Steroids (L70.8: ALT (if systemic) (Within baseline reference limits (L70.8)).
Common Symptoms & Clinical Signs
- • Autoimmune diseases such as lupus and multiple sclerosis
- • Skin conditions such as eczema and rashes
- • Presentation of Steroids (L70.8): post-inflammatory hyperpigmentation, facial in Steroids (L70.8: flushing, or pitted)
- • Secondary Steroids clinical sign: recurrent flares triggered in Steroids (L70.8: by UV exposure,)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Steroids Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | L70.8 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Dermatology: Acne, Eczema, Psoriasis & Rosacea | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Fasting Lipids & in Steroids (L70.8: ALT (if systemic) | Within baseline reference limits (L70.8) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Steroids (L70.8: & hs-CRP) | 25(OH)D 40–65 ng/mL (L70.8) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Affected Body Surface in Steroids (L70.8: Area (BSA /) | Clear or Almost Clear (IGA 0–1) (L70.8) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Steroids
Treatment selection for Steroids depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Steroids)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Tralokinumab plus skin-applied corticosteroids in adults with severe eczema and: What a 277-Participant Study Found Tralokinumab 300 mg plus TCS as needed was effective and well tolerated in patients with severe AD whose disease was not adequately controlled with CSA or who had contraindications to oral CSA. The British journal of dermatology • 2022-03-15 • Phase III Randomized Trial | N = 277 | 93/100 | PMID 34698371 ↗ |
| New Insights on Baricitinib in combination with skin-applied steroids on eczema symptoms, quality: What a 329-Participant Study Found Baricitinib plus TCS vs. Journal of the European Academy of Dermatology and Venereology : JEADV • 2021-07-15 • Phase III Randomized Trial | N = 329 | 93/100 | PMID 33834521 ↗ |
| New Insights on Benefits and safety of lebrikizumab combined with skin-applied corticosteroids in: What a 286-Participant Study Found Consistent with global data, lebrikizumab demonstrated clinical improvements with a positive benefit-risk profile in Japanese adults and adolescents with moderate-to-severe AD through 16 weeks. Current medical research and opinion • 2025-01-15 • Phase III Randomized Trial | N = 286 | 93/100 | PMID 39625230 ↗ |
| New Insights on Rapid and sustained improvements in itch and quality of life with upadacitinib: What a 901-Participant Study Found Results: This analysis included 901 patients. The Journal of dermatological treatment • 2024-12-15 • Phase III Randomized Trial | N = 901 | 93/100 | PMID 38697950 ↗ |
| New Insights on Lebrikizumab Combined with skin-applied Corticosteroids Improves Patient-reported: What a 286-Participant Study Found All PRO endpoints for the study were met; patients in the lebrikizumab in combination with applied to the skin corticosteroids groups demonstrated statistically significant and clinically meaningful improvements compared with... Acta dermato-venereologica • 2024-09-09 • Phase III Randomized Trial | N = 286 | 93/100 | PMID 39248292 ↗ |
Steroids Patient Community & “People Like Me” Threads
Filter Steroids community threads and patient logs by age, biological sex, dosage, and treatment duration.